SRPT
Sarepta Therapeutics, Inc.
Is SRPT Halal?
Gene-therapy and RNA biotech focused on rare diseases — permissible pharmaceutical research with passing current asset ratios and disclosed low interest income.
What You Should Know
Sarepta Therapeutics, Inc. develops and markets RNA-based and gene therapies for rare diseases. Its March 31, 2026 Form 10-Q reports $3,178.934 million of assets, $838.162 million of convertible and other long-term debt, $464.45 million of cash, $188.739 million of short-term investments, $394.817 million of accounts receivable and $730.803 million of first-quarter revenue. Debt/assets is 26.37%, liquidity/assets is 20.55%, receivables-plus-cash/assets is 27.03% and disclosed investment income interest/revenue is 0.87%. The pharmaceutical activity is generally permissible, while collaboration and product-level classification remain incomplete.
⚠️ Concerns
- •Debt/assets is 26.37% and should be confirmed under market-cap methods
- •Receivables-plus-cash/assets is 27.03% and should be re-screened as products scale
- •Disclosed investment income interest is 0.87% of revenue; follow the chosen purification guidance
- •Collaboration and gene-therapy revenue are not allocated into a universal prohibited-activity numerator
- •Clinical and regulatory setbacks can change the ratios quickly
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-15.
838.162 / 3,178.934
653.189 / 3,178.934
859.267 / 3,178.934
6.36 / 730.803
- Financial
- Pass
- Overall
- Incomplete
Debt/assets is 26.37%, liquidity/assets is 20.55%, receivables plus cash/assets is 27.03% and interest income/revenue is 0.87%, below the examined limits; activity remains incomplete.
- Financial
- Pass
- Overall
- Incomplete
Debt/assets is 26.37%, liquidity/assets is 20.55% and receivables plus cash/assets is 27.03%, below the examined MSCI limits; activity remains incomplete.
- Financial
- Pass
- Overall
- Incomplete
Debt/assets and liquidity/assets are below the examined Malaysia SAC limits; activity remains incomplete and this is not an official classification.
- Financial
- Not calculated
- Overall
- Incomplete
A licensed historical market-cap series is not stored, so market-cap denominator methods are not estimated from a current spot price.
Business-activity disclosure
Sarepta develops and markets RNA-based and gene therapies for rare diseases. Pharmaceutical research and treatment are generally permissible, while product approvals, collaborations and end-use disclosures require continuing review.
Limitation: The filing does not allocate all product, collaboration and pipeline revenue into a universal prohibited-activity numerator.
Purification
Sarepta discloses $6.36 million of investment income interest, but no scholar-approved purification percentage is inferred.
Inputs, assumptions and primary sources
- Amounts are USD millions from Sarepta's March 31, 2026 Form 10-Q.
- Debt uses the reported $838.162 million long-term debt balance; convertible debt is included and operating leases are excluded.
- Cash and cash equivalents are $464.45 million and short-term investments are $188.739 million; long-term investments are not added without a security-level classification.
- Accounts receivable, net is $394.817 million and first-quarter total revenues are $730.803 million, including product and collaboration revenue.
- Investment income interest is $6.36 million; the filing does not provide a universal prohibited-revenue numerator for every therapy or collaboration.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →